An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX

Scientific publication - Journal Article uoadl:2955239 102 Read counter

Unit:
Faculty of Medicine
Title:
An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX
Languages of Item:
English
Abstract:
Empty abstract
Publication year:
2016
Authors:
Dimopoulos, M
Oriol, A
Nahi, H
San Miguel, J
Bahlis, N
Rabin, N
Orlowski, R
Komarnicki, M
Suzuki, K
Plesner, T
others
Journal:
Haematologica-the hematology journal
Volume:
101
Number:
Suppl 1
Pages:
342
Main subject category:
Health Sciences
The digital material of the item is not available.